Table 3 Model results
Cases overall | Cases without MI | Cases with MI | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Model A (SARE) | Model B (SCRARE) | Model A (SARE) | Model B (SCRARE) | Model A (SARE) | Model B (SCRARE) | |||||||
Wr | We | Wr | We | Wr | We | Wr | We | Wr | We | Wr | We | |
Observations | 401 | 401 | 401 | 401 | 401 | 401 | 401 | 401 | 401 | 401 | 401 | 401 |
Pseudo R-squared | 0.4186 | 0.4265 | 0.4261 | 0.4352 | 0.3813 | 0.3894 | 0.3895 | 0.3992 | 0.3986 | 0.4005 | 0.3995 | 0.4023 |
β (SE) | ||||||||||||
Estimate of CHD prevalencea | 10.01 (0.88)*** | 10.48 (1.63)*** | 9.87 (0.88)*** | 10.38 (0.88)*** | 8.99 (0.81)*** | 9.44 (0.81)*** | 8.87 (0.81)*** | 9.35 (0.81)*** | 1 (0.14)*** | 1.01 (0.14)*** | 0.99 (0.14)*** | 1 (0.14)*** |
GISD 2012 | 0.16 (0.1) | 0.1 (0.11) | 0.15 (0.1) | 0.11 (0.1) | 0.13 (0.09) | 0.07 (0.09) | 0.12 (0.09) | 0.08 (0.09) | 0.04 (0.02)** | 0.04 (0.02)** | 0.04 (0.02)** | 0.04 (0.02)*** |
Cath labsb | 40.62 (16.33)** | 45.92 (19.83)** | 53.41 (18.16)*** | 56.68 (18.32)*** | 37.64 (14.96)** | 43.36 (15.77)*** | 49.34 (16.79)*** | 53.53 (16.95)*** | 2.91 (2.87) | 2.97 (2.91) | 3.35 (2.92) | 3.49 (2.95) |
W × Cath labsb | 77.18 (47.71) | 80.41 (49.84) | 68.44 (44.18) | 74.64 (46.56) | 6.35 (7.3) | 7.59 (7.14) | ||||||
Constant | –143.81 (165.58) | –174.98 (142.44) | –167.02 (165.36) | –170.68 (173.94) | –103.5 (151.88) | –147.53 (160.93) | –123.82 (151.71) | –143.93 (160.46) | –20.05 (28.46) | –15.35 (28.81) | –21.27 (28.46) | –14.21 (28.78) |
ρ | 0.67 (0.05)*** | 0.72 (0.06)*** | 0.66 (0.05)*** | 0.71 (0.06)*** | 0.68 (0.05)*** | 0.72 (0.06)*** | 0.68 (0.05)*** | 0.72 (0.06)*** | 0.3 (0.06)*** | 0.31 (0.09)*** | 0.3 (0.06)*** | 0.31 (0.09)*** |